Skip to content
Review Open access

Treatment-resistant hypertension in the primary care setting

Sep 2026 · Journal of Osteopathic Medicine · 0 citations · 66 references
Medicine

TL;DR

Addressing factors that contribute to pseudo-resistance is of utmost significance in managing a patient with apparent treatment resistance or even refractory hypertension in the primary care setting, and this work aims to address factors to improve care for hypertension in the primary care setting.

Abstract

Abstract Context Rates of treatment-resistant hypertension in the United States are increasing despite our better understanding of underlying mechanisms, lifestyle and pharmacologic approaches, and with refinement of treatment goals. Distinguishing treatment resistance from pseudo-resistance or even refractory hypertension is increasingly clinically difficult, and understanding the influences that dictate resistance in the primary care setting is needed to improve patient outcomes. Objectives Herein, we will review current definitions of treatment resistance, pseudo-resistance, and refractory hypertension, and we will discuss patient- and provider-related factors that influence resistance, facilitating a more holistic approach to care. Methods We conducted a comprehensive narrative review utilizing PubMed as the basis for our medical literature search. We employed a combination of Medical Subject Headings (MeSH) terms and free-text keywords, including “treatment resistant hypertension,” “resistant hypertension,” “refractory hypertension,” and “pseudo-resistance.” No language or date restrictions were applied for the initial search to help with wide capture of available literature that included a broad range of study designs, clinical guidelines, and consensus statements. Results Resistance is classically defined as blood pressure (BP) >130/80 mm Hg despite the use of three or more antihypertensives including a diuretic at optimized doses and with appropriate combination of drugs having complementary mechanisms of action, or with controlled BP requiring four or more anti-hypertensive drugs. Improper BP measurement techniques, underdosing antihypertensives, therapeutic inertia, nonadherence, and even a white coat effect contribute to pseudo-resistance. Conclusions Addressing factors that contribute to pseudo-resistance is of utmost significance in managing a patient with apparent treatment resistance or even refractory hypertension in the primary care setting. Recent strategies for managing true resistance include ambulatory BP monitoring or out-of-office home BP measurement, assessing underlying secondary causes, rational drug design to optimize the drug regimen, and a collaborative multidisciplinary approach with guidance from hypertension specialists. Addressing the factors that underlie pseudo-resistance and treatment resistance is consequential to improve not only major cardiovascular morbidity and mortality but also quality of life and tolerability of complex treatment regimens. Herein, we aim to address factors to improve care for hypertension in the primary care setting.

Read PDF

Similar papers

Review Open access Oct 2026

Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension

Treatment selection should prioritize treatments with demonstrated superiority over baseline treatment, including spironolactone, baxdrostat, and radiofrequency renal denervation in patients with resistant or uncontrolled hypertension.

Angelo Laino, R. Piccolo, A. Vitale et al. · 0 citations
Review Oct 2026

Resistant Hypertension: State of the Art Review.

Resistant hypertension, defined as blood pressure above target despite treatment with at least three antihypertensive agents (including a diuretic) or controlled blood pressure requiring four or more medications, affects over 140 million individuals globally and confers increased risks of heart failure, stroke, and chr...

M. S. Khan, Muhammad Sameer Arshad, Michael E. Hall et al. · 0 citations
Review Nov 2026

Abstract 7481: Resistant Hypertension in Male Veterans - Gaps in Secondary Workup and Guideline-Directed Therapy

Background: Resistant hypertension (RH) is uncontrolled blood pressure (BP) despite ≥ 3 antihypertensive agents including a diuretic, or controlled BP requiring ≥ 4 agents, affecting 8.5-20% of hypertensive U.S. adults. Veterans represent a high-risk population with significant medical and psychosocial comorbidities...

Sahithi Reddi, Lisa Fisher · 0 citations
Nov 2026

Abstract 9824: Prevalence of Diagnostic Testing in Diagnosed and Undiagnosed Resistant Hypertension

Background: Resistant hypertension, defined as hypertension refractory to three antihypertensive agents or hypertension which requires at least four agents to control, is associated with substantially increased cardiovascular risk. Current guidelines recommend evaluation for secondary hypertension in patients with r...

Nolan R. Martin, S. Hallaj, Eileen Kim et al. · 0 citations
Review Oct 2026

Present and future of ulta-low- and low-dose triple combination therapy in hypertension: a clinical practice perspective.

INTRODUCTION It is increasingly recognized that initial monotherapy is insufficiently effective for sustained blood pressure (BP) control in the large majority of people with hypertension. Ultra-low- and low-dose combination therapy has emerged as a strategy to overcome limitations of conventional monotherapy-based ste...

Moo-Yong Rhee, J. Jang, Ki-Chul Sung et al. · 0 citations
Review Nov 2026

Abstract 11510: A Multidisciplinary Resistant Hypertension Clinic Improves Secondary Hypertension Screening and Blood Pressure Control

About 20% of patients with hypertension are resistant. Patients with resistant hypertension are at increased risk for adverse cardiovascular disease. These patients often have a treatable secondary cause and could benefit from a structured referral pathway and specialized clinic to improve screening, optimize treatment...

Trish Tran, Alexander Haile, Lilit Vardanyan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.